OneSource Specialty Pharma Ltd
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]
- Market Cap ₹ 21,424 Cr.
- Current Price ₹ 1,871
- High / Low ₹ 2,250 / 1,163
- Stock P/E 122
- Book Value ₹ 517
- Dividend Yield 0.00 %
- ROCE 6.42 %
- ROE 4.14 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 3.62 times its book value
- Promoter holding has decreased over last quarter: -4.46%
- Company has a low return on equity of -16.8% over last 3 years.
- Promoters have pledged or encumbered 25.0% of their holding.
- Debtor days have increased from 92.4 to 124 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|
21 | 132 | 39 | 172 | 1,300 | 1,381 | |
93 | 228 | 156 | 254 | 930 | 942 | |
Operating Profit | -72 | -96 | -117 | -82 | 370 | 438 |
OPM % | -337% | -72% | -303% | -48% | 28% | 32% |
1 | 4 | -525 | -143 | -95 | -89 | |
Interest | 16 | 68 | 48 | 89 | 162 | 147 |
Depreciation | 34 | 70 | 109 | 76 | 135 | 134 |
Profit before tax | -121 | -230 | -799 | -390 | -22 | 68 |
Tax % | 0% | 0% | 0% | 0% | -187% | |
-121 | -230 | -799 | -390 | 19 | 68 | |
EPS in Rs | 1.69 | |||||
Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 114% |
TTM: | 243% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 37% |
TTM: | 190% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -17% |
Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Equity Capital | 2 | 4 | 4 | 4 | 11 |
Reserves | 777 | 1,012 | 783 | 394 | 5,909 |
386 | 1,154 | 864 | 571 | 942 | |
98 | 275 | 363 | 457 | 635 | |
Total Liabilities | 1,262 | 2,445 | 2,014 | 1,426 | 7,497 |
633 | 1,231 | 1,361 | 863 | 3,200 | |
CWIP | 382 | 440 | 334 | 188 | 206 |
Investments | 53 | 52 | 5 | 20 | 2,848 |
194 | 722 | 314 | 355 | 1,243 | |
Total Assets | 1,262 | 2,445 | 2,014 | 1,426 | 7,497 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
-115 | -420 | -165 | -109 | -47 | |
-210 | -685 | -66 | 506 | -300 | |
381 | 1,159 | 118 | -384 | 417 | |
Net Cash Flow | 56 | 55 | -112 | 13 | 70 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Debtor Days | 38 | 101 | 35 | 118 | 124 |
Inventory Days | 87 | 1,720 | 2,354 | 665 | 233 |
Days Payable | 758 | 408 | 1,606 | 419 | 143 |
Cash Conversion Cycle | -633 | 1,414 | 784 | 363 | 214 |
Working Capital Days | -2,423 | -1,288 | -6,731 | -873 | -49 |
ROCE % | -10% | -12% | -12% | 6% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
26 Sep - 26-Sep-2025: OneSource board approved composite merger of SSPL, BSL, Steriscience SG, SPSPL; specified share-exchange ratios.
- Investor Presentation 26 Sep
-
Closure of Trading Window
26 Sep - Trading window closed Oct 1, 2025 until 48 hours after results for quarter ended Sept 30, 2025.
-
Voting Results Of The Annual General Meeting Held On 22Nd September, 2025
24 Sep - AGM 22-09-2025: six resolutions passed—audited FY2025 financials, director reappointment, cost/secretarial auditors, RPTs with Strides.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
22 Sep - 18th AGM on Sep 22, 2025: adopted FY25 financials; reappointed director; approved auditors, cost auditor remuneration, RPTs with Strides.
Annual reports
Concalls
-
Sep 2025TranscriptNotesPPT
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.